Glenmede Trust’s Guardant Health GH Stock Holding History

Glenmede Trust’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$440K	Sell	2,936 -1,929	-40%	-$210K	﹤0.01%	1031
2026 Q1	$449K	Buy	4,865 +12	+0.2%	+$1.21K	﹤0.01%	1006
2025 Q4	$496K	Buy	+4,853	New	+$434K	﹤0.01%	950
2020 Q4	–	Sell	-1,075	Closed	-$120K	–	1621
2020 Q3	$120K	Hold	1,075	–	–	﹤0.01%	1124
2020 Q2	$87K	Sell	1,075 -5,924	-85%	-$477K	﹤0.01%	1189
2020 Q1	$546K	Hold	6,999	–	–	﹤0.01%	877
2019 Q4	$546K	Buy	6,999 +922	+15%	+$66.4K	﹤0.01%	877
2019 Q3	$387K	Buy	6,077 +5,542	+1,036%	+$488K	﹤0.01%	966
2019 Q2	$46K	Buy	535 +335	+168%	+$25.6K	﹤0.01%	1712
2019 Q1	$15K	Buy	+200	New	+$11.1K	﹤0.01%	2213

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Glenmede Trust's GH Position: Q2 2026 in Review

Glenmede Trust reduced its Guardant Health (GH) stake by 40% in Q2 2026, selling an estimated $210K and leaving 2,936 shares worth $440K. The position accounts for ﹤0.01% of the portfolio, ranked #1031.

Glenmede Trust first reported a position in GH in Q1 2019 and has held it in 10 quarters since. The position peaked at $546K in Q1 2020. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.

Glenmede Trust held 2,936 shares of Guardant Health worth $440K as of Q2 2026.
Glenmede Trust sold 1,929 Guardant Health shares in Q2 2026, an estimated $210K.
Guardant Health made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #1031 holding.
Glenmede Trust first reported a position in Guardant Health in Q1 2019 and has held it in 10 quarters since.
Glenmede Trust's Guardant Health position peaked at $546K in Q1 2020.
597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.